Pilot RCT finds oxygen therapy trial feasible for children with pneumonia and hypoxaemia in Malawi
This pilot randomized controlled trial assessed the feasibility of conducting a three-armed trial comparing standard care (no oxygen), low-flow nasal cannula (LFNC), and high-flow nasal cannula (HFNC) oxygen therapy. The study enrolled 21 children aged 1-59 months with WHO-defined pneumonia and an SpO2 of 90-93% at a district hospital in Malawi. The primary outcome was feasibility, defined as an average of ≤2 protocol deviations per participant.
The trial was found to be feasible, with an average of 0.8 protocol deviations per participant (16 deviations across 21 participants). A secondary outcome, treatment failure within 14 days, occurred in 3 of 21 participants (14.3%). No participants withdrew from the study. Safety data, including adverse events and tolerability, were not reported.
Key limitations include the pilot nature of the study and its small sample size (n=21). Funding sources and conflicts of interest were not reported. The study was designed to assess trial feasibility, not the efficacy or causality of oxygen therapy. Therefore, the results should not be interpreted as evidence for or against the use of LFNC or HFNC in this population. The findings support the feasibility of conducting a larger, definitive trial in this specific Malawian hospital setting.